A Small Molecule Drug Discovery Platform to Target Cancer Causing microRNAs

Project Summary Abstract The pharmaceutical and biotech industries are targeting various RNA classes to develop new drugs MicroRNAs miRNAs participate in widespread regulation of cell function and contribute to a spectrum of human diseases especially cancer making miRNAs a drug target class of particular interest Due to delivery issues and poor bioavailability oligonucleotides based therapies have proven unsuccessful in widespread miRNA targeting As such pharmaceutical and biotech companies are pursuing miRNA targeted small molecule therapies However to efficiently identify drug like miRNA targeting small molecules that therapeutically alter biological activity new tools are in demand To meet this demand Nymirum is developing the first ever platform to rapidly accurately and cost efficiently identify and optimize small molecules that therapeutically target cancer causing microRNAs Project Narrative miRNAs represent the largest RNA drug target class with significant implications in cancer Nymirum is developing the first ever platform to rapidly accurately and cost efficiently identify and optimize small molecules that therapeutically target cancer causing microRNAs